DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Still a Buy?

Shares of DBV Technologies S.A. (NASDAQ:DBVT) gapped up prior to trading on Monday. The stock had previously closed at $9.75, but opened at $10.11. DBV Technologies shares last traded at $9.9350, with a volume of 38,862 shares traded.

Analysts Set New Price Targets

DBVT has been the topic of several research analyst reports. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Citigroup restated a “market outperform” rating on shares of DBV Technologies in a research note on Wednesday, September 30th. Citizens Jmp upped their target price on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a report on Thursday, October 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Stock Up 1.5%

The company has a fifty day moving average price of $11.79 and a 200-day moving average price of $17.04.

Hedge Funds Weigh In On DBV Technologies

Several large investors have recently made changes to their positions in DBVT. Vivo Capital LLC grew its position in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after buying an additional 205,943 shares during the period. ADAR1 Capital Management LLC purchased a new stake in shares of DBV Technologies during the 1st quarter worth about $21,159,000. Perceptive Advisors LLC purchased a new stake in shares of DBV Technologies during the 1st quarter worth about $20,146,000. Atika Capital Management LLC grew its position in shares of DBV Technologies by 31.1% during the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company’s stock valued at $5,667,000 after acquiring an additional 64,419 shares during the period. Finally, Elmind Capital LP acquired a new stake in shares of DBV Technologies during the 1st quarter valued at about $5,536,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.